胺类化合物作为治疗年龄相关疾病的治疗目的的青调节剂的特权来源
Mazzarine Dotou1,2, Aurore L'honoré1, Roba Moumné2
1Sorbonne Université, Faculty of Sciences and Engineering, IBPS, UMR 8256 CNRS-SU, ERL INSERM U1164, Biological Adaptation and Ageing, F-75252 Paris, France.
Journal of natural products
|March 4, 2024
概括
Piper 类化合物,如 piperlongumine,由于它们的抗氧化和抗炎性质,在对抗细胞衰老和与年龄有关的疾病方面表现有前途. 这些天然化合物为衰老提供了潜在的治疗益处.
科学领域:
- 自然产品化学 自然产品化学
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 自然是生物活性化合物的重要来源,用于药物发现.
- 植物衍生化合物在衰老和衰老研究中具有重要意义.
- Piper 化物表现出与衰老相关的抗氧化,抗炎和神经保护性质.
研究的目的:
- 审查Piper类化合物的老年调节潜力,重点关注piperlongumine及其衍生物.
- 探索这些化合物在与年龄有关的疾病中的治疗应用.
主要方法:
- 对Piper类化合物及其对细胞衰老的影响研究的文献综述.
- 对 piperlongumine 和相关化合物的生物活性研究的分析.
- 对与年龄有关的疾病的潜在治疗策略的调查.
主要成果:
- Piper 类化合物,特别是 piperlongumine,在调节衰老方面表现出显著的潜力.
- 这些化合物具有抵消细胞衰老过程的特性.
- 有证据表明,它们在治疗与年龄相关的疾病方面具有实用性.
结论:
- Piper 类化合物代表了一类有前途的天然化合物,用于治疗衰老的治疗干预.
- Piperlongumine及其衍生品需要进一步研究,以开发抗衰老药物.
- 它们的神经调节作用为管理与年龄相关的疾病提供了新的途径.
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
673
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
673
Direct-Acting Cholinergic Agonists: Therapeutic Uses
740
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
740
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
958
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
958
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
125
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
125
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268


